Ad hoc announcement pursuant to Art. 53 LR
U.S. clinical hold remains in place; study continues in all other countries
Company initiates expansion of clinical sites and enrollment
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, and Morristown, NJ, USA – September 22, 2026, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA:
Ad hoc announcement pursuant to Art. 53 LR
Total proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development
Milan, Italy, and Morristown, NJ, USA, September 3, 2026, – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the
Ad hoc announcement pursuant to Art. 53 LR
ENIGMA-TRS 1 is Phase 3 international, one-year, randomized, double-blind, placebo-controlled study in 600+ patients; 12-week study
Ad hoc announcement pursuant to Art. 53 LR
Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in
Milan, Italy, and Morristown, NJ, USA – May 28, 2026, 3:30 pm CEST – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the
Ad hoc announcement pursuant to Art. 53 LR
Newron reports a pause in enrollment of new study participants in US centers of ENIGMA-TRS 2 study
Pause of enrollment limited to US
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, and Morristown, NJ, USA – March 24, 2026, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
